Proteomic Profiling of Serum Derived Exosomes from Prostate Cancer Patients
type: CreativeWork
description: Touted among the major achievements in the diagnosis and management of Prostate cancer (PCa) in the past few decades has been, the dramatic decline of men with advanced/metastatic PCa at diagnosis coupled with a significant improvement ( >90%) in the five and ten year survival rates of the disease. Non-palpable PCa (potentially clinically treatable disease) now accounts for 70-80% of all newly diagnosed cases of PCa. Preceding these changes by about a decade was the introduction of Prostatic Specific Antigen (PSA) into clinical practice; first as biomarker for monitoring response to therapy and subsequently as a complementary screening tool. It is not surprising then that a cause-effect relationship has been suggested. Like a double-edged sword, the use of PSA as a screening tool has also been blamed for the rise of unnecessary prostate related invasive procedures including biopsies and surgeries. Some of the documented criticisms of PSA include its lack of specificity (elevated in inflammation) for PCa and the difficulty of establishing a cut-off value that is highly sensitive and specific for the disease. It is estimated that perhaps up to half of the PCa diagnosis are patients whose tumors would have been clinically undetectable had PSA not been included in the screening process. The dissatisfaction with PSA has created opportunities to search for novel biomarkers for screening and monitoring of treatment in PCa. Some of the more novel biomarkers that have been examined as potential replacements for PSA are the RNA product prostate cancer antigen-3 (PCA 3), the enzyme alpha methylacyl-CoA, and the gene fusion product TMPRSS2-ERG. More recently Zhang, Casiano and colleagues described an increased predominance of autoantibodies to Cyclin-B1 in the sera of PCa patients compared to controls with Benign Prostatic Hyperplasia (BPH). All these efforts are in different stages of maturity but yet to have ground breaking clinical impact. We hereby examined the role of exos…
abstract: Touted among the major achievements in the diagnosis and management of Prostate cancer (PCa) in the past few decades has been, the dramatic decline of men with advanced/metastatic PCa at diagnosis coupled with a significant improvement ( >90%) in the five and ten year survival rates of the disease. Non-palpable PCa (potentially clinically treatable disease) now accounts for 70-80% of all newly diagnosed cases of PCa. Preceding these changes by about a decade was the introduction of Prostatic Specific Antigen (PSA) into clinical practice; first as biomarker for monitoring response to therapy and subsequently as a complementary screening tool. It is not surprising then that a cause-effect relationship has been suggested. Like a double-edged sword, the use of PSA as a screening tool has also been blamed for the rise of unnecessary prostate related invasive procedures including biopsies and surgeries. Some of the documented criticisms of PSA include its lack of specificity (elevated in inflammation) for PCa and the difficulty of establishing a cut-off value that is highly sensitive and specific for the disease. It is estimated that perhaps up to half of the PCa diagnosis are patients whose tumors would have been clinically undetectable had PSA not been included in the screening process. The dissatisfaction with PSA has created opportunities to search for novel biomarkers for screening and monitoring of treatment in PCa. Some of the more novel biomarkers that have been examined as potential replacements for PSA are the RNA product prostate cancer antigen-3 (PCA 3), the enzyme alpha methylacyl-CoA, and the gene fusion product TMPRSS2-ERG. More recently Zhang, Casiano and colleagues described an increased predominance of autoantibodies to Cyclin-B1 in the sera of PCa patients compared to controls with Benign Prostatic Hyperplasia (BPH). All these efforts are in different stages of maturity but yet to have ground breaking clinical impact. We hereby examined the role of exos…
author: Turay, David
language: English
keywords: Anatomy, Biochemistry, Male Urogenital Diseases, Medical Cell Biology, Medical Immunology, Oncology, Urogenital System, Prostatic Neoplasms; Proteomics; Exosomes; Prostatic Hyperplasia; Prostate-Specific Antigen; Biomarkers; Tumor; Lymphocytes, Serum-derived Exosomes; Prostate cancer; Stress survival proteins
date published: 2016-06-01T07:00:00Z
date modified: 2026-07-24T02:52:38Z
provider: Loma Linda University
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: Loma Linda University